From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis.
Nucleic Acid Ther
; 33(4): 234-237, 2023 08.
Article
em En
| MEDLINE
| ID: mdl-37581487
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oligonucleotídeos Antissenso
/
Esclerose Lateral Amiotrófica
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article